Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

Figure 3 Claudin 18. 2 and survival. A: There was no significant correlation between tumor-specific survival and claudin 18.2 expression in tumor cells (41 vs 39 patients; median survival 13 mo vs 11 mo; P = 0.176); B: 20 vs 15 patients in stage I disease with median survival 24 mo vs 14 mo (P = 0.666); C: 12 vs 8 patients in stage II disease with median survival 9 mo vs 16 mo (P = 0.480); D: 4 vs 8 patients in stage III disease with median survival 15 mo vs 8 mo (P = 0.012); E: 5 vs 8 patients in stage IV disease with median survival 7 mo vs 3 mo (P = 0.009); F: 36 vs 31 patients in M0 disease with median survival 15 mo vs 13 mo (P = 0.351); G: 5 vs 8 patients in M1 disease with median survival 7 mo vs 4 mo (P = 0.024); H: 32 vs 18 patients in N0 disease with median survival 14 mo vs 13 mo (P = 0.825); I: 9 vs 21 patients in N1/N2 disease with median survival 11 mo vs 9 mo (P = 0.920). P values were obtained via log-rank-test. AJCC: American Joint Committee on Cancer; H-score: Histoscore.